Intech Investment Management LLC Buys 36,104 Shares of Hologic, Inc. (NASDAQ:HOLX)

Intech Investment Management LLC boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 64.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,300 shares of the medical equipment provider’s stock after buying an additional 36,104 shares during the period. Intech Investment Management LLC’s holdings in Hologic were worth $6,654,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in HOLX. First Horizon Advisors Inc. grew its stake in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Brooklyn Investment Group grew its position in Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC increased its stake in Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 169 shares in the last quarter. Finally, Loomis Sayles & Co. L P raised its holdings in Hologic by 29.3% in the third quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after buying an additional 183 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Stephens reissued an “overweight” rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. BNP Paribas raised Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Citigroup decreased their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Argus cut Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Raymond James reissued an “outperform” rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Trading Up 0.3 %

Shares of Hologic stock opened at $61.98 on Wednesday. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The company’s fifty day simple moving average is $66.72 and its 200-day simple moving average is $74.37. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market capitalization of $13.91 billion, a PE ratio of 19.55, a P/E/G ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.